Second-Line Medications for Women Aged 10 to 50 Years With Idiopathic Generalized Epilepsy.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cerulli Irelli Emanuele, Cocchi Enrico, Gesche Joanna, Peña-Ceballos Javier, Caraballo Roberto H, Lattanzi Simona, Strigaro Gionata, Morano Alessandra, Moloney Patrick B, Ferlazzo Edoardo, Pascarella Angelo, Mazzeo Adolfo, D'Aniello Alfredo, Pizzanelli Chiara, Milano Chiara, Giuliano Loretta, Viola Veronica, Mostacci Barbara, Fortunato Francesco, Pulitano Patrizia, Burani Margherita, Meletti Stefano, Pignatta Pietro, Perulli Marco, Battaglia Domenica, Rosati Eleonora, Delanty Norman, Di Gennaro Giancarlo, Gambardella Antonio, Labate Angelo, Operto Francesca F, Giallonardo Anna T, Beier Christoph P, Di Bonaventura Carlo, Women with Epilepsy Treatment Options and Research (WETOR) study group
Аннотация
OBJECTIVE: To evaluate the effectiveness and safety of substitution monotherapy vs add-on therapy as second-line options for women who might become pregnant with IGE after failure of first-line antiseizure medications (ASMs) other than valproic acid.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective comparative effectiveness cohort study at 18 primary, secondary, and tertiary adult and children epilepsy centers across 4 countries, analyzing data from 1995 to 2023. Participants were women aged 10 to 50 years diagnosed with IGE who were prescribed a second line of ASM.
MAIN OUTCOMES AND MEASURES: Treatment failure (TF), defined as the replacement or addition of a second ASM due to ineffectiveness, was compared between patients receiving ASM add-on or substitution monotherapy using inverse probability of treatment weighting (IPTW)-adjusted Cox proportional hazards regression. Exploratory analyses were also conducted to assess the effectiveness of individual ASMs and various ASM combinations.
RESULTS: This study included 249 women with a median (IQR) age of 18.0 (15.5-22.0) years. Among them, 146 (58.6%) received an add-on regimen, and 103 (41.4%) received substitution monotherapy. During follow-up, TF occurred in 48 patients (32.9%) receiving add-on therapy and 36 (35.0%) using substitution monotherapy, with no significant differences between groups (IPTW-adjusted hazard ratio [HR], 0.89; 95% CI, 0.53-1.51; P = .69). ASM discontinuation due to ineffectiveness or adverse effects occurred in 36 patients (24.7%) receiving add-on therapy and 29 (28.2%) receiving substitution monotherapy, showing no significant differences (IPTW-adjusted HR, 0.97; 95% CI, 0.57-1.65; P = .92). Rates of ASM discontinuation due to adverse effects only were low in both groups, occurring in 13 patients (9.0%) receiving add-on therapy and 9 (8.7%) receiving a substitution monotherapy. Among add-on regimens other than valproic acid, the combination of levetiracetam and lamotrigine demonstrated a lower risk of TF compared with other combinations with levetiracetam plus other ASM (adjusted HR, 2.41; 95% CI, 1.12-5.17; P = .02) and lamotrigine plus other ASM (adjusted HR, 4.03; 95% CI, 1.73-9.39; P = .001). However, valproic acid remained the most effective second-line ASM when considering individual agents.
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study of second-line treatment strategies for women with IGE, no significant differences were observed between substitution monotherapy and add-on therapy.